If approved, MCO-010 would be the first treatment to restore vision in legally blind RP patients without needing genetic ...

AAVantgarde is now initiating ‘CELESTE’, a first-in-human Phase 1/2 clinical trial in the United States, to evaluate the safety, tolerability, and initial efficacy of AAVB-039 in patients with ...

Female sex hormones can significantly enhance the progression of the rare neurodegenerative eye disease retinitis pigmentosa (RP), according to a preclinical study by researchers at UT Southwestern ...

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova.